Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

695

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies

Interventions

DRUG: AZD9574
DRUG: Temozolomide (TMZ)
DRUG: [11C]AZ1419 3391
DRUG: Trastuzumab Deruxtecan (T-DXd)
DRUG: Datopotamab Deruxtecan (Dato-DXd)

Sponsor

AstraZeneca